Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,477JPY
26 Jul 2017
Change (% chg)

¥-3 (-0.20%)
Prev Close
¥1,480
Open
¥1,479
Day's High
¥1,482
Day's Low
¥1,470
Volume
1,049,500
Avg. Vol
1,251,164
52-wk High
¥2,134
52-wk Low
¥1,470

Latest Key Developments (Source: Significant Developments)

Sunovion’s Latuda receives Health Canada approval to treat adolescents with schizophrenia
Friday, 21 Jul 2017 12:10pm EDT 

July 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Sunovion’s Latuda® (lurasidone HCI) receives Health Canada approval to treat adolescents with schizophrenia.Sunovion's Latuda receives Health Canada approval to treat adolescents with schizophrenia.  Full Article

Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101
Sunday, 2 Jul 2017 11:24pm EDT 

July 3(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).  Full Article

Sunovion's Sun-101/eflow NDA recieves FDA approval
Friday, 30 Jun 2017 08:00am EDT 

June 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Sunovion announces FDA acceptance for review of new drug application resubmission for Sun-101/eflow® (glycopyrrolate) for the treatment of chronic obstructive pulmonary disease (COPD).Expected action date by FDA under prescription drug user fee act (PDUFA) is December 15, 2017​‍​.  Full Article

Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards
Monday, 29 May 2017 04:55am EDT 

May 29(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan-Generally Accepted Accounting Principles.IFRS effective from financial statement for fiscal year ending March 2018.  Full Article

Sunovion submits supplemental new drug application to FDA for Aptiom
Monday, 13 Mar 2017 09:00am EDT 

Sumitomo Dainippon Pharma Co Ltd <4506.T>: Sunovion submits supplemental new drug application to FDA for use of Aptiom (eslicarbazepine acetate) for the treatment of partial-onset seizures in children 4 years of age and older . Sunovion - in SNDA submission, Sunovion will also include data from three clinical trials conducted by partner Bial-Portela .Sunovion - planning a phase 3 clinical study in children younger than four years of age.  Full Article

Sumitomo Dainippon Pharma to buy Tolero Pharmaceuticals via unit
Wednesday, 21 Dec 2016 02:45am EST 

Sumitomo Dainippon Pharma Co Ltd <4506.T> :Says co plans to fully acquire 100 percent stake in Tolero Pharmaceuticals, Inc via co's US-based unit, at up to $780 million (advisory fees excluded), in Feb. 2017.  Full Article

Sumitomo Dainippon Pharma unit to buy 100 pct stake in Cynapsus Therapeutics Inc. at $624 mln
Monday, 3 Oct 2016 11:40pm EDT 

Sumitomo Dainippon Pharma <4506.T>:Says its subsidiary will buy 100 percent stake in Cynapsus Therapeutics Inc. at $624 million by the end of Dec..  Full Article

Ignore Sumitomo Dainippon Pharma alert, BRIEF
Monday, 3 Oct 2016 11:02pm EDT 

Please ignore an alert and BRIEF on Sumitomo Dainippon Pharma Co <4506.T> and Cynapsus Therapeutics Inc , which were based on a Sept. 1 news release reposted by Sumitomo Dainippon's parent company. The original story was issued on Sept. 1. [nL3N1BC57T] STORY_NUMBER:.  Full Article

Cynapsus says Sunovion Pharma entitled to termination fee of $24 mln if deal terminated - SEC filing
Thursday, 1 Sep 2016 07:31am EDT 

Cynapsus Therapeutics : Sunovion Pharma entitled to termination fee in amount of $24 million which shall be paid by co if deal terminated - SEC filing Source: (http://bit.ly/2bT5Y0k ) Further company coverage: [CTH.TO] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sumitomo Dainippon Pharma to offer early-retirement program
Tuesday, 30 Aug 2016 03:25am EDT 

Sumitomo Dainippon Pharma Co Ltd <4506.T>: Says it to offer an early-retirement program to employees, who are above 45 years old as of Nov. 30 and worked more than five years (except part of employees) . Says offering period from Sep. 26 to Oct. 14 . Says the employees who take up the offer will retire on Nov. 30 .Says a premium will be added to the normal retirement payment, and the company will provide re-employment support to the retiring employees.  Full Article

BRIEF-Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. has entered into a definitive agreement to divest the U.S. market rights of Sunovion’s three ciclesonide products to Covis Pharma B.V. on July 13(US Eastern Time)